Page 65 - Priority Review News Today

STOCKHOLM, April 4, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today announced that...

STOCKHOLM, April 4, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today announced that its partner Eisai has published an article about long-term health outcomes of anti-amyloid-beta

– First treatment option combining an antibody-drug conjugate plus a PD-1 inhibitor in this patient population –BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced the U.S. Food and Drug Administration (FDA) has granted PADCEV® (enfortumab vedotin-e...

-- CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 -- BERKELEY, Calif., April 04, 2023 -- Caribou Biosciences, Inc. , a leading clinical-stage CRISPR... | April 4, 2023

Enfortumab vedotin-ejfv (Padcev, Astellas Pharma and Seagen Inc) with pembrolizumab (Keytruda, Merck) approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB and its partner Eisai has presented new findings on lecanemab , an anti-amyloid beta protofibril antibody for the treatment of Alzheimers... | April 3, 2023

STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanemab (generic name, U.S. brand name: LEQEMBI)

STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner...

A rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, cell and... | April 3, 2023

-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- ... | April 3, 2023